

## Marialuisa Sponziello

### PERSONAL INFORMATION

**Nationality** Italia

**POSITION** Assistant Professor, Department of Translational and Precision Medicine, SAPIENZA University of Rome

### WORK EXPERIENCE

03/12/2018–Present

#### Assistant Professor

SAPIENZA University of Rome, Rome (Italy)

SC 06/N1 Technology and methodology in medicine and nursing sciences SSD MED/46

Biotechnology and methods in laboratory medicine

PROJECT TITLE: Preoperative Molecular Stratification of Thyroid Cancer: diagnostic, prognostic and predictive value

01/08/2017–31/07/2018 **Post Doctoral Fellowship**

SAPIENZA University of Rome - Department of Internal Medicine and Medical Specialties, Roma (Italy)

PROJECT TITLE: Use of molecular biomarkers in FNA specimens to improve diagnostic accuracy of cytology and personalize management of thyroid cancer patients

01/06/2014–31/05/2017 **Post Doctoral Fellowship**

SAPIENZA University of Rome - Department of Internal Medicine and Medical Specialties, Roma (Italy)

PROJECT TITLE: Diagnostic and prognostic role of microRNAs in Papillary Thyroid Carcinoma (PTC)

01/02/2011–31/01/2014 **Post Doctoral Fellowship**

SAPIENZA University of Rome - Department of Internal Medicine and Medical Specialties, Roma (Italy)

PROJECT TITLE: Isolation and characterization of cancer stem cells, genotyping and gene expression analysis

24/10/2012–13/12/2013 **Visiting Research Fellowship**

Thomas Jefferson University – Kimmel Cancer Center – Department of Cancer Biology - Cancer Genomics Laboratory, Philadelphia (United States)

PROJECT TITLE: Next-generation sequencing based approaches applied to thyroid cancer biology

01/11/2007–31/10/2010 **PhD Student**

SAPIENZA University of Rome, Department of Internal Medicine and Medical Specialties, Rome (Italy)

PROJECT TITLE: BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas: in vivo and in vitro analysis.

01/06/2007–30/11/2007

**Research Fellow**

SAPIENZA University of Rome - Department of Cellular and Development Biology, Roma (Italy)

TITLE: Molecular characterization of wine yeasts

EDUCATION AND TRAINING

01/03/2018–30/01/2019

**Advanced Training Course in Pedagogy and Medical Teaching**

SAPIENZA University of Rome, Faculty of Medicine and Dentistry

01/11/2007–31/10/2011

**PhD degree in Biotechnologies in Clinical Medicine**

SAPIENZA University of Rome - Department of Internal Medicine and Medical Specialties, Roma (Italy)

THESIS TITLE: BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas: in vivo and in vitro analysis

2005–30/03/2007

**MS Degree in Genomic Biotechnologies**

SAPIENZA University of Roma - Department of Cellular and Development Biology, Roma (Italy)

THESIS TITLE: Characterization of KIGUT2, a gene of the glycerol-3-phosphate shuttle, in *Kluyveromyces lactis*

Graduation with 110/100 and highest honours (*summa cum laude*)

01/10/2001–30/01/2005

**BS Degree in Biotechnology**

SAPIENZA University of Rome - Department of Cellular and Development Biology, Rome (Italy)

THESIS TITLE: Effect of a motogen factor (Hepatocyte growth factor) on proteins associated with stress fibers in neural precursors.

1995–2001

**High School Diploma**

Liceo Scientifico “Virgilio”, Copertino (LE) (Italy)

High School focusing on science

Graduation with 100/100

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language English

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C1	C2	C1	C1	C2

Levels A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user  
[Common European Framework of Reference for Languages - Self-assessment grid](#)

**Job-related skills**

Research activity in the field of thyroid cancer biology; thyroid cancer genomics and genetics; molecular markers for early cancer diagnosis, prognosis and targeted therapy; liquid biopsy in thyroid cancer; network medicine; next-generation sequencing; bioinformatics; thyroid cancer stem cells

## ADDITIONAL INFORMATION

**Honours and awards** 2011: SIMI (Società Italiana di Medicina Interna) Prize for Best Oral Communication; Title: *Tumor angiogenesis and expression of proangiogenic molecular markers in papillary thyroid carcinomas: a limited role for the BRAF V600E mutation?* (112th SIMI Conference, Rome, 2011).

2017: SIE (Società Italiana Endocrinologia) Prize for Best Poster Presentation; Title: *Whole exome sequencing identifica una mutazione germinale di MET in una famiglia affetta da carcinoma midollare della tiroide RET wild-type* (39° Congresso Nazionale SIE, Rome, 21-24 June 2017)

2020: Achievement of National Scientific qualification as associate in the Italian higher education system, in the call 2018/2020 for the disciplinary field of 06/N1 - Technology and methodology in medicine and nursing sciences

## Oral Presentations at National or International Conferences

- 112th SIMI Conference, Rome, 22-25 Ottobre 2011. TITLE: Tumor angiogenesis and expression of proangiogenic molecular markers in papillary thyroid carcinomas: a limited role for the BRAF V600E mutation?
- Forum tumore della tiroide: nuove frontiere della diagnosi e terapia. Rome, November 19, 2016. TITLE: Analisi molecolare dei preparati citologici: quale metodologia
- Workshop "Strategie Terapeutiche per il trattamento del cancro della tiroide: contributo delle nuove tecnologie. Catanzaro, February 9-10, 2018. TITLE: Next-Generation Sequencing
- 2° Forum Noduli della Tiroide: Nuove frontiere nella diagnosi e terapia. Rome, April 21, 2018. TITLE: Analisi molecolare su preparati citologici e su biopsia liquida
- 3° Forum Noduli della Tiroide: Nuove frontiere nella diagnosi e terapia". Rome, April 6, 2019. TITLE: Siamo pronti per l'applicazione del test molecolare nella pratica clinica? Domande e risposte
- 1ST ITALIAN THYROID PRECEPTORSHIP. THE CUTTING EDGE STAGE IN THYROID RESEARCH. Rome, April 12-13, 2019. TITLE: Liquid Biopsy
- Genetica e Genomica: strategie e strumenti per una medicina innovativa". Udine, May 14, 2019. TITLE: Il punto di vista dell'utilizzatore finale
- World Congress on Thyroid Cancer 3.5. Rome, June 20-22, 2019. TITLE: Targeted Next-Generation Sequencing of Thyroid Fine-Needle Aspirates Identified Incidental Germline Findings
- 4° Forum Noduli della Tiroide: Nuove frontiere nella diagnosi e terapia. Online, Oct 03, 2020. TITLE: "Ruolo dei test molecolari nella classificazione del rischio di malignità dei noduli tiroidei"
- 5° Forum Noduli della Tiroide: Nuove frontiere nella diagnosi e terapia. Online, Apr 17, 2021. TITLE: "Come l'analisi cito-molecolare può modificare l'approccio ai noduli tiroidei"
- 6° Forum Noduli della Tiroide: Nuove frontiere nella diagnosi e terapia. Rome, July 1, 2022. TITLE: "Breaking news: L'analisi molecolare dei preparati citologici tiroidei"
- 44th Annual Meeting of the European Thyroid Association. Brussels, Sept 10-13, 2022. TITLE: "Real-world performance of a novel dual-component molecular assay in cytologically indeterminate thyroid nodules: a single institutional experience"

- Courses and Certifications**
- 05.03.2010 al 07.03.2010 - *ABI PRISM 3130* - Applied Biosystem - Rome, Italy
  - 20.03.2010 al 21.03.2010 - *ABI Prism 7900* - Applied Biosystem - Rome, Italy
  - 4.11.2013 - *DNA Sequencing Variant Analysis Methods and Applications Workshop* - Golden Helix - Children's Hospital of Philadelphia - Philadelphia, PA, USA
  - 05.10.2015 al 07.10.2015 - *High Throughput Sequencing data analysis* - HTS BeMM 2015 - BEMM - Rome, Italy
  - 19.10.2015 al 22.10.2015 - *Gene Expression profiling with HTS: RNA\_Seq data Analysis (RNASeq2015)* - CINECA - Rome, Italy
  - 19.05.2016 al 20.05.2016 - *MiSeq System* - Illumina - Rome, Italia
  - 22.06.2016 - *QuantStudio 3D Digital PCR System* - Thermo Fisher Scientific - Rome, Italy
  - 12.07.2016 al 13.07.2016 - *Ion Chef + S5 Systems Workflow training* - Thermo Fisher Scientific - Monza (MI), Italy
  - 11.09.2017 al 15.09.2017 - *Python for Life Scientists* - ELIXIR-IIB - Rome, Italy

- Fundings**
- 2008 FIRB-Futuro in Ricerca (prot. RBFR082XL7\_003) MINISTERO DELL'ISTRUZIONE, DELL'UNIVERSITÀ E DELLA RICERCA. TITLE: Isolation and characterization of cancer stem cells, genotyping and gene expression analysis. ROLE: Co-Investigator
  - 2008 Ricerche di ATENEO FEDERATO (ex ricerche di FACOLTÀ) di Scienze delle Politiche Pubbliche e Sanitarie SPPS (prot.C26F089TF5). SAPIENZA University of Rome TITLE: Identification of novel genetic predisposing factors in familial non medullary thyroid cancer ROLE: Co-Investigator
  - 2009 Ricerche UNIVERSITARIE (prot. C26A094AMM). SAPIENZA University of Rome TITLE: Differentiated Thyroid Cancers: somatic mutations and their prognostic role ROLE: Co-Investigator
  - 2015 Avvio alla Ricerca (prot. C26N155X55). SAPIENZA University of Rome. TITLE: Identification of long non-coding RNAs acting as miRNA sponges in Papillary Thyroid Cancer. ROLE: Principal Investigator
  - 2018 Ricerca di Ateneo - Progetti Grandi (prot. RG11816432DC1F0F). SAPIENZA University of Rome. TITLE: Predictive molecular signature associated with radioiodine-resistance in thyroid cancer: in vivo and in vitro studies ROLE: Co-Investigator
  - 2019 Ricerca di Ateneo - Progetti Piccoli (prot. RP11916B8919C921). SAPIENZA University of Rome. TITLE: Identification of Incidental Germline Findings through in-house FNA testing of thyroid nodule patients who underwent somatic genotyping ROLE: Principal-Investigator
  - 2020 Ricerca di Ateneo - Progetti Piccoli (prot. RP11916B8919C921). SAPIENZA University of Rome. TITLE: Exploring the malignant potential of the thyroid follicular adenomas ROLE: Principal-Investigator
  - 2021 Ricerca di Ateneo - Progetti Medi (prot. RM12117A87DFBA61). SAPIENZA University of Rome. TITLE: Real-world performance of a novel dual-component molecular assay in cytologically indeterminate thyroid nodules: a single institutional experience. ROLE: Principal-Investigator

**Reviewer Activities** BMC Medical Genetics, Endocrine, European Journal of Endocrinology, Frontiers in Endocrinology, International Journal of Endocrinology, Oncotarget, RSC Advances

**Teaching Activity**

2019 – present. Course: *Basic Medical Scientific Methodology I*; Medicine and Surgery D; Faculty of Medicine and Dentistry; SAPIENZA University of Rome, Rome, Italy

2019 – present. Course: *Basic Medical Scientific Methodology II*; Medicine and Surgery D; Faculty of Medicine and Dentistry; SAPIENZA University of Rome, Rome, Italy.

2019 – present. Course: *Pre-Clinical Medical Scientific Methodology II*; Medicine and Surgery D; Faculty of Medicine and Dentistry; SAPIENZA University of Rome, Rome, Italy.

2019 – present. Member of the Teachers College in the PhD Program “*Innovative Biomedical Technologies in Clinical Medicine*” (Code: 30100) at Department of Precision and Translational Medicine, SAPIENZA University of Rome, Rome, Italy.

June 3, 2020. Lecturer in the PhD Program “Life Sciences” at University of Catanzaro during the course “*New technologies of cellular and molecular biology in translational research*”. Lecture Title “*Next-generation Sequencing: history, platforms and applications*”

2021 – present. Member of the Quality Assurance Committee at Medicine and Surgery D Degree Programme at Faculty of Medicine and Dentistry, SAPIENZA University of Rome, Rome, Italy.

May 31, 2022. Lecturer in the “*Corso di Alta Formazione in Diagnosi e Terapia della Patologia Nodulare della Tiroide*” at Università degli Studi di Roma Unitelma Sapienza. Lecture Title “*Introduzione alle tecniche di biologia molecolare*”

- Bibliometric Indicators** H-INDEX: 21 (Banca Dati *Scopus*)  
 Publications: 66 (first author in 15, last author in 6; corresponding in 4).  
 Total citations: 1226 (*Scopus*)  
 Total impact factor: 465.886 (*JCR*)  
 Average impact factor: 7.28 (*JCR*)
- Patent** Patent No.102019000024009: “New method for the diagnosis of a thyroid tumor and related kit”. Approved by the Patent Technical Committee of SAPIENZA – Filed on December 13, 2019. Issued November 29, 2021.  
 Inventors: FILETTI Sebastiano, DURANTE Cosimo, VERRIENTI Antonella, SPONZIELLO Marialuisa, GRANI Giorgio
- Publications**
1. Saliola M, **Sponziello M**, D’Amici S, Lodi T, Falcone C. Characterization of KIGUT2, a gene of the glycerol-3-phosphate shuttle, in *Kluyveromyces lactis*. *FEMS Yeast Res.* 2008 Aug;8(5):697-705. doi: 10.1111/j.1567-1364.2008.00386.x.
  2. **Sponziello M**, Scipioni A, Durante C, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D. Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines. *J Endocrinol Invest.* 2010 Jan;33(1):2-6. doi: 10.3275/6522.
  3. Castellone MD, Verrienti A, Magendra Rao D, **Sponziello M**, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: functional characterization. *Clin Endocrinol (Oxf).* 2010 Oct;73(4):529-34. doi:10.1111/j.1365-2265.2009.03757.x.
  4. Saliola M, D’Amici S, **Sponziello M**, Mancini P, Tassone P, Falcone C. The transdehydrogenase genes KINDE1 and KINDI1 regulate the expression of KIGUT2 in the yeast *Kluyveromyces lactis*. *FEMS Yeast Res.* 2010 Aug 1;10(5):518-26. doi:10.1111/j.1567-1364.2010.00631.x.
  5. **Sponziello ML**, Bruno R, Durante C, D’Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. *Horm Metab Res.* 2011 Jan;43(1):22-5. doi: 10.1055/s-0030-1265226.
  6. Durante C, Tallini G, Puxeddu E, **Sponziello M**, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol.* 2011 Sep;165(3):455-63. doi:10.1530/EJE-11-0283.
  7. Voce P, D’Agostino M, Moretti S, **Sponziello M**, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. *Oncol Rep.* 2011 Nov;26(5):1075-80. doi:10.3892/or.2011.1422.
  8. Russo D, Costante G, Bruno R, **Sponziello M**, Tamburrano G, Dima M, Sacco R, Giacomelli L, Durante C, Filetti S. TSH receptor extracellular region mutations in thyroid

functioning nodules: further evidence for the functional role of this region in the receptor activation. *Endocrine*. 2011 Dec;40(3):492-4. doi:10.1007/s12020-011-9525-7.

9. D'Agostino M, Voce P, Celano M, **Sponziello M**, Moretti S, Maggisano V, Verrienti A, Durante C, Filetti S, Puxeddu E, Russo D. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. *Thyroid*. 2012 Feb;22(2):138-44. doi: 10.1089/thy.2011.0060.
10. Celano M\*, **Sponziello M\***, Tallini G, Maggisano V, Bruno R, Dima M, Di Oto E, Redler A, Durante C, Sacco R, Filetti S, Russo D. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. *Endocrine*. 2013 Feb;43(1):147-53. doi:10.1007/s12020-012-9747-3. \**Co-first*
11. Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, **Sponziello M**, Migaldi M, Navarra M, Bianchi G, Filetti S, Russo D. Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. *J Endocrinol*. 2013 Jan 18;216(2):125-33 doi: 10.1530/JOE-12-0495.
12. Maggisano V, Puppini C, Celano M, D'Agostino M, **Sponziello M**, Micali S, Navarra M, Damante G, Filetti S, Russo D. Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells. *Endocrine*. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4.
13. **Sponziello M**, Lavarone E, Pegolo E, Di Loreto C, Puppini C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. *Endocrinology*. 2013 Sep;154(9):3043-53. doi:10.1210/en.2013-1028.
14. D'Agostino M\*, **Sponziello M\***, Puppini C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. *J Mol Endocrinol*. 2014 Jan 30;52(2):121-31. doi: 10.1530/JME-13-0160. \**Co-first*
15. Londin ER, Clark P, **Sponziello M**, Kricka LJ, Fortina P, Park JY. Performance of exome sequencing for pharmacogenomics. *Per Med*. 2014;12(2):109-115. doi: 10.2217/PME.14.77.
16. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, **Sponziello M**, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. *J Clin Endocrinol Metab*. 2014 May;99(5):E832-40. doi:10.1210/jc.2013-3351.
17. Puppini C, Durante C, **Sponziello M**, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. *Endocrine*. 2014 Nov;47(2):528-36. doi:10.1007/s12020-014-0204-3.
18. **Sponziello M**, Durante C, Boichard A, Dima M, Puppini C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. *Mol Cell Endocrinol*. 2014 Jul 5;392(1-2):8-13. doi: 10.1016/j.mce.2014.04.016.



19. Park JY, Clark P, Londin E, **Sponziello M**, Kricka LJ, Fortina P. Clinical exome performance for reporting secondary genetic findings. *Clin Chem*. 2015 Jan;61(1):213-20. doi:10.1373/clinchem.2014.231456.
20. Sponziello M, Verrienti A, Rosignolo F, De Rose RF, Pecce V, Maggisano V, Durante C, Bulotta S, Damante G, Giacomelli L, Di Gioia CR, Filetti S, Russo D, Celano M. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. *Endocrine*. 2015 Nov;50(2):434-41. doi:10.1007/s12020-015-0586-x.
21. Passon N, Bregant E, **Sponziello M**, Dima M, Rosignolo F, Durante C, Celano M, Russo D, Filetti S, Damante G. Somatic amplifications and deletions in genome of papillary thyroid carcinomas. *Endocrine*. 2015 Nov;50(2):453-64. doi:10.1007/s12020-015-0592-z.
22. Rosignolo F, Maggisano V, **Sponziello M**, Celano M, Di Gioia CR, D'Agostino M, Giacomelli L, Verrienti A, Dima M, Pecce V, Durante C. Reduced expression of THR $\beta$  in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression. *J Endocrinol Invest*. 2015 Dec;38(12):1283-9. doi:10.1007/s40618-015-0309-4.
23. Verrienti A, Carbone A, Bellitti P, Fabiano MC, De Rose RF, Maranghi M, Lucia P, Durante C, Rosignolo F, Pecce V, **Sponziello M**, Puppini C, Costante G, Bruno R. A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2. *Endocr Pract*. 2015 Nov;21(11):1248-54. doi:10.4158/EP15838.OR.
24. Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, **Sponziello M**, Damante G, Russo D, Durante C. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. *Endocrine*. 2016 Jul;53(1):145-56. doi:10.1007/s12020-015-0739-y.
25. **Sponziello M**, Durante C, Filetti S. HAP2 Mutation and Nonmedullary Thyroid Cancer. *N Engl J Med*. 2015 Nov 19;373(21):2085-6. doi: 10.1056/NEJMc1511631#SA3.
26. Fabiano MC, Verrienti A, Carbone A, **Sponziello M**, Bellitti P, Bruno R. Genotype-Phenotype Correlation in a MODY 2 Family: An Under-Diagnosed Disease. 2016 *Journal of Diabetes Mellitus*; 6:263-268. <http://dx.doi.org/10.4236/jdm.2016.64027>.
27. **Sponziello M**, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti S, Damante G, Russo D, Bulotta S. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. *Mol Cell Endocrinol*. 2016 Aug 15;431:123-32. doi:10.1016/j.mce.2016.05.007.
28. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, **Sponziello M**, Trulli F, Verrienti A, Filetti S, Durante C. Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. *J Clin Endocrinol Metab*. 2016 Aug;101(8):3036-44. doi: 10.1210/jc.2016-1440.
29. Rosignolo F, **Sponziello M**, Durante C, Puppini C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G. Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma. *PLoS One*. 2016 Jun 1;11(6):e0156658. doi:10.1371/journal.pone.0156658.
30. Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, **Sponziello M**, Rosignolo F, de Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C. RET mutation and increased angiogenesis in medullary thyroid carcinomas. *Endocr Relat Cancer*. 2016 Aug;23(8):665-76. doi:10.1530/ERC-16-0132.
31. Celano M, Mignogna C, Rosignolo F, **Sponziello M**, Iannone M, Lepore SM, Lombardo GE, Maggisano V, Verrienti A, Bulotta S, Durante C, Di Loreto C, Damante G, Russo D. Expression of YAP1 in aggressive thyroid cancer. *Endocrine*. 2018 Jan;59(1):209-212. doi: 10.1007/s12020-017-1240-6.

32. Maggisano V, Celano M, Lombardo GE, Lepore SM, **Sponziello M**, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, Filetti S, Damante G, Russo D, Bulotta S. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. *Mol Cell Endocrinol*. 2017 Jun 15;448:34-40. doi:10.1016/j.mce.2017.03.007.
33. Rosignolo F\*, **Sponziello M\***, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, Durante C, Filetti S, Verrienti A. Identification of thyroid-associated serum microRNA profiles and their potential use in thyroid cancer follow-up. *J Endocr Soc*. 2017 Jan 12;1(1):3-13. doi: 10.1210/ajs.2016-1032. \**Co-first*
34. Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, Durante C, Grani G, Lamartina L, Forte S, Martinetti D, Giuffrida D, Russo D, Basolo F, Filetti S, **Sponziello M**. MicroRNA-based molecular classification of papillary thyroid carcinoma. *Int J Oncol*. 2017 May;50(5):1767-1777. doi:10.3892/ijo.2017.3960.
35. Celano M, Mio C, **Sponziello M**, Verrienti A, Bulotta S, Durante C, Damante G, Russo D. Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer. *Mol Cell Endocrinol*. 2017 Jun 2. pii:S0303-7207(17)30305-2. doi: 10.1016/j.mce.2017.05.036.
36. **Sponziello M**, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzì AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, Filetti S, Durante C, Verrienti A. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer. *Hum Mutat*. 2018 Mar;39(3):371-377. doi: 10.1002/humu.23378.
37. Mio C, Conzatti K, Baldan F, Allegri L, **Sponziello M**, Rosignolo F, Russo D, Filetti S, Damante G. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells. *Oncol Rep*. 2018 Feb;39(2):582-588. doi: 10.3892/or.2017.6152. \**Co-last*
38. Di Costanzo A, Belardinilli F, Bailetti D, **Sponziello M**, D'Erasmus L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, and Arca M. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. *Sci Rep*. 2018 Feb 27;8(1):3702. doi: 10.1038/s41598-018-21939-0.
39. **Sponziello M**, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, Durante C, Filetti S, Fadda G. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma. *Endocrine*. 2018 Nov;62(2):492-495. doi: 10.1007/s12020-018-1611-7.
40. Pecce V\*, **Sponziello M\***, Damante G, Rosignolo F, Durante C, Lamartina L, Grani G, Russo D, di Gioia CR, Filetti S, Verrienti A. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency. *PLoS Genet*. 2018 Oct 15;14(10):e1007678. doi: 10.1371/journal.pgen.1007678. \**Co-first*
41. Maggisano V, Celano M, Lepore SM, **Sponziello M**, Rosignolo F, Pecce V, Verrienti A, Baldan F, Mio C, Allegri L, Maranghi M, Falcone R, Damante G, Russo D, Bulotta S. Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells. *Endocrine*. 2019 Mar;63(3):545-553. doi: 10.1007/s12020-018-01836-2.
42. Falcone R, Conte F, Fiscon G, Pecce V, **Sponziello M**, Durante C, Farina L, Filetti S, Paci P, Verrienti A. BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response. *Endocrine*. 2019 Mar 8. doi: 10.1007/s12020-019-01890-4.



43. Celano M, Maggisano V, Lepore SM, **Sponziello M**, Pecce V, Verrienti A, Durante C, Maranghi M, Lucia P, Bulotta S, Damante G, Russo D. Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells. *Int J Endocrinol*. 2019 Feb 14;2019:5031696. doi:10.1155/2019/5031696.
44. Grani G, Ramundo V, Falcone R, Lamartina L, Montesano T, Biffoni M, Giacomelli L, **Sponziello M**, Verrienti A, Schlumberger M, Filetti S, Durante C. Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound. *J Clin Endocrinol Metab*. 2019 Jun 17. pii: jc.2019-00962. doi: 10.1210/jc.2019-00962.
45. Verrienti A, **Sponziello M**, Durante C, Filetti S, Grani G. Comment on: BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. *Clin Endocrinol (Oxf)*. 2020 May;92(5):482-483. doi:10.1111/cen.14103.
46. Grani G, Ramundo V, Verrienti A, **Sponziello M**, Durante C. Thyroid hormone therapy in differentiated thyroid cancer. *Endocrine*. 2019 Oct;66(1):43-50. doi: 10.1007/s12020-019-02051-3.
47. Falcone R, **Sponziello M\***, Carletti R, Di Gioia C, Nardi F, Mio C, Pecce V, Abballe L, Grani G, Ramundo V, Damante G, Durante C, Filetti M, Roberto M, Marchetti P, Verrienti A. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. *Endocrine*. 2020 Apr;68(1):230-232. doi: 10.1007/s12020-020-02221-8. *\*Corresponding author*
48. Ramundo V, **Sponziello M**, Falcone R, Verrienti A, Filetti S, Durante C, Grani G. Low-risk papillary thyroid microcarcinoma: Optimal management toward a more conservative approach. *J Surg Oncol*. 2020 May;121(6):958-963. doi: 10.1002/jso.25848.
49. Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, **Sponziello M**. Update on Fundamental Mechanisms of Thyroid Cancer. *Front Endocrinol (Lausanne)*. 2020 Mar 13;11:102. doi:10.3389/fendo.2020.00102.
50. **Sponziello M**, Brunelli C, Verrienti A, Grani G, Pecce V, Abballe L, Ramundo V, Damante G, Russo D, Lombardi CP, Durante C, Rossi ED, Straccia P, Fadda G, Filetti S. Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules. *Endocrine*. 2020 May;68(2):458-465. doi: 10.1007/s12020-020-02271-y.
51. Grani G, **Sponziello M**, Pecce V, Ramundo V, Durante C. Contemporary thyroid nodule evaluation and management. *J Clin Endocrinol Metab*. 2020 Jun 3:dga322. doi: 10.1210/clinem/dgaa322.
52. Verrienti A, Pecce V, Abballe L, Ramundo V, Falcone R, Inanloo Nigi Jak F, Brunelli C, Fadda G, Bosco D, Ascoli V, Carletti R, Di Gioia C, Grani G, **Sponziello M**. Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue. *Endocrine*. 2020 Jun 6. doi: 10.1007/s12020-020-02372-8.
53. Pecce V, Verrienti A, Abballe L, Carletti R, Grani G, Falcone R, Ramundo V, Durante C, Di Gioia C, Russo D, Filetti S, **Sponziello M**. Loss of Function SETD2 Mutations in Poorly Differentiated Metastases from Two Hürthle Cell Carcinomas of the Thyroid. *Cancers (Basel)*. 2020 Jul 14;12(7):1892. doi: 10.3390/cancers12071892.
54. Verrienti A, Carbone A, Cito DS, **Sponziello M**, Pecce V, Bruno R. Long-term disease recurrence in the adipose tissue and striated muscles of a minimally invasive papillary thyroid carcinoma. *Endocrine*. 2021 Jun;72(3):937-939. doi: 10.1007/s12020-020-02558-0.
55. Sodo A, Verri M, Palermo A, Naciu AM, **Sponziello M**, Durante C, Di Gioacchino M, Paolucci A, di Masi A, Longo F, Crucitti P, Taffon C, Ricci MA, Crescenzi A. Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas. *Diagnostics (Basel)*. 2020 Dec 29;11(1):43. doi: 10.3390/diagnostics11010043.

56. Grani G, **Sponziello M**, Filetti S, Durante C. Molecular analysis of fine-needle aspiration cytology in thyroid disease: where are we? *Curr Opin Otolaryngol Head Neck Surg*. 2021 Apr 1;29(2):107-112. doi: 10.1097/MOO.0000000000000698.
57. Mio C, Verrienti A, Pecce V, **Sponziello M\***, Damante G\*. Rare germline variants in DNA repair-related genes are accountable for papillary thyroid cancer susceptibility. *Endocrine*. 2021 Apr 5. doi: 10.1007/s12020-021-02705-1. *\*Co-last*
58. Pecce V, Verrienti A, Fiscon G, **Sponziello M**, Conte F, Abballe L, Durante C, Farina L, Filetti S, Paci P. The role of FOSL1 in stem-like cell reprogramming processes. *Sci Rep*. 2021 Jul 19;11(1):14677. doi: 10.1038/s41598-021-94072-0.
59. Sibilio P, Bini S, Fiscon G, **Sponziello M**, Conte F, Pecce V, Durante C, Paci P, Falcone R, Norata GD, Farina L, Verrienti A. In silico drug repurposing in COVID-19: A network-based analysis. *Biomed Pharmacother*. 2021 Oct;142:111954. doi: 10.1016/j.biopha.2021.111954.
60. Capriglione F, Verrienti A, Celano M, Maggisano V, **Sponziello M**, Pecce V, Gagliardi A, Giacomelli L, Aceti V, Durante C, Bulotta S, Russo D. Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer. *Endocrine*. 2022 Jan;75(1):185-193. doi: 10.1007/s12020-021-02847-2.
61. Verrienti A, Carbone A, **Sponziello M**, Pecce V, Cito DS, Bruno R. Papillary thyroid carcinoma as first and isolated neoplastic disease in a Lynch syndrome family member with a germline MLH1 mutation. *Endocrine*. 2022 Jun;77(1):199-202. doi: 10.1007/s12020-022-03048-1.
62. Pecce V\*, **Sponziello M\***, Bini S, Grani G, Durante C, Verrienti A. Establishment and maintenance of thyroid organoids from human cancer cells. *STAR Protoc*. 2022 May 15;3(2):101393. doi: 10.1016/j.xpro.2022.101393. *\*Co-first*
63. Maggisano V, Capriglione F, Verrienti A, Celano M, Gagliardi A, Bulotta S, **Sponziello M**, Mio C, Pecce V, Durante C, Damante G, Russo D. Identification of Exosomal microRNAs and Their Targets in Papillary Thyroid Cancer Cells. *Biomedicines*. 2022 Apr 21;10(5):961. doi: 10.3390/biomedicines10050961.
64. Gentili M, Martini L, **Sponziello M**, Becchetti L. Biological Random Walks: multi-omics integration for disease gene prioritization. *Bioinformatics*. 2022 Jul 6:btac446. doi: 10.1093/bioinformatics/btac446. *\*Corresponding author*
65. Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, **Sponziello M**, Pecce V, Lucia P, Verrienti A, Filetti S, Durante C. The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment. *Endocrine*. 2022 Jul 8:1-5. doi: 10.1007/s12020-022-03131-7.
66. Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, **Sponziello M**, Pecce V, Verrienti A, Filetti S, Durante C. The legacy of the COVID-19 pandemics for thyroid cancer patients: towards the application of clinical practice recommendations. *Endocrine*. 2022 Jul 20:1-4. doi: 10.1007/s12020-022-03132-6.
67. Verrienti A, Grani G, **Sponziello M**, Pecce V, Damante G, Durante C, Russo D, Filetti S. Precision oncology for RET-related tumors. *Front Oncol*. 2022 Aug 24;12:992636. doi: 10.3389/fonc.2022.992636.

**Book**

Durante C, Rosignolo F, **Sponziello M**, Verrienti A, Filetti S: Circulating RNAs as biomarkers in thyroid cancer. In: *Atlas of Thyroid and Neuroendocrine Tumors Markers*, pp. 93-103 Springer

**Rome, October 04, 2022**